Why the ITC is in vogue for pharma patent disputes
The number of pharma patent complaints at the International Trade Commission was up greatly last year. Natalie Rahhal analyses what is driving this and what benefits the ITC brings for pharmaceutical companies
Data and practitioners suggest that
pharmaceutical companies are beginning to look to the
International Trade Commission (ITC) as an appealing alternate
venue for patent litigation.
Pharmaceutical and biotech companies have a well-documented
history of conservatism. This makes sense: according to...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.